Takeda and Advinus announce new discovery collaboration

Takeda has announced a new three-year partnership with Advinus Therapeutics focusing on the development of novel drug targets for major therapeutic areas.

Research-based pharmaceutical company Advinus will take the lead in creating investigational new drug (IND)-ready compounds for predefined targets in the fields of inflammation, central nervous system conditions and metabolic disease.

Takeda will receive worldwide commercial rights to drug candidates emerging from this alliance, while Advinus is guaranteed to receive at least $36 million (22.35 million pounds) in research funding, $9 million in developmental milestone fees and up to $45 million per product in commercial and regulatory milestone payments.

Dr Paul Chapman, general manager of the pharmaceutical research division of Takeda, said: "We are very excited to partner with Advinus as they have innovative approaches to efficiently generate INDs that will further strengthen Takeda's drug discovery capabilities, while also enhancing our pipeline."

Last month, the company received European regulatory approval for the new short bowel syndrome therapy Revestive, which was developed alongside partner NPS Pharmaceuticals.